HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

AbstractINTRODUCTION:
We sought to determine predictors for early and late biochemical recurrence following radical prostatectomy among localized prostate cancer patients.
METHODS:
The study included localized prostate cancer patients treated with radical prostatectomy (RP) at the University of Southern California from 1988 to 2008. Competing risks regression models were used to determine risk factors associated with earlier or late biochemical recurrence, defined using the median time to biochemical recurrence in this population (2.9 years after radical prostatectomy).
RESULTS:
The cohort for this study included 2262 localized prostate cancer (pT2-3N0M0) patients who did not receive neoadjuvant or adjuvant therapies. Of these patients, 188 experienced biochemical recurrence and a subset continued to clinical recurrence, either within (n=19, 10%) or following (n=13, 7%) 2.9 years after RP. Multivariable stepwise competing risks analysis showed Gleason score ≥7, positive surgical margin status, and ≥pT3a stage to be associated with biochemical recurrence within 2.9 years following surgery. Predictors of biochemical recurrence after 2.9 years were Gleason score 7 (4+3), preoperative prostate-specific antigen (PSA) level, and ≥pT3a stage.
CONCLUSIONS:
Higher stage was associated with biochemical recurrence at any time following radical prostatectomy. Particular attention may need to be made to patients with stage ≥pT3a, higher preoperative PSA, and Gleason 7 prostate cancer with primary high-grade patterns when considering longer followup after RP.
AuthorsAhva Shahabi, Raj Satkunasivam, Inderbir S Gill, Gary Lieskovsky, Sia Daneshmand, Jacek K Pinski, Mariana C Stern
JournalCanadian Urological Association journal = Journal de l'Association des urologues du Canada (Can Urol Assoc J) 2016 Jan-Feb Vol. 10 Issue 1-2 Pg. E17-22 ISSN: 1911-6470 [Print] Canada
PMID26858782 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: